SEALD AS is a biotech company that is developing an innovative personalised approach to treating bile duct cancer. Bile duct cancer is a rare, but very deadly form of cancer, afflicting three per cent of people with cancer of the digestive system. At present, the five-year survival rate is two to five per cent, the mean life expectancy is only 11 months, and there is no known cure.
Utilising an entirely new, innovative approach and the latest methods, SEALD AS aspires to find the right treatment for the individual patient by combining molecular biomarkers, DNA sequencing, ex vivo drug sensitivity analysis and live xenograft animal models.
This approach is based on the concept of personalised medicine where the treatment is tailored to the individual patient. We do this on the basis of the specific gene mutations causing the cancer and a cancer drug sensitivity screening (CDSS) on the patients’ own living cancer cells. The patient is then given his or her own zebrafish “avatar”. This is done by transplanting the patient’s living cancer cells into the zebrafish, which is then treated by one of our treatment options or a new medicine combination indicated by the patient’s own CDSS. We plan to run the first clinical study at the Norwegian Radium Hospital in 2019.
Would you like to know more?